Sugi Predict

Sugi Predict / Compounds / SCHEMBL2387532

SCHEMBL2387532

SCHEMBL2387532

COC(=O)C1CC(=O)c2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLS O94925 1/20 0.46
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ P2RX7 Q99572 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ ITGA4 P13612 1/20 0.40
▸ POLB P06746 2/20 0.39
▸ HTR2C P28335 2/20 0.39
▸ PKM P14618 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ AR P10275 1/20 0.38
▸ HSD11B1 P28845 1/20 0.38
▸ AKR1C3 P42330 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ EDNRB P24530 1/20 0.38
▸ EDNRA P25101 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6392161 0.84 PIN1 (0.40) GLSMEN1KMT2AL3MBTL1P2RX7
SCHEMBL17605695 0.84 GLS (0.41) GLSMEN1KMT2AL3MBTL1P2RX7
SCHEMBL17386339 0.83 ALDH1A1 (0.50) GLSMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL15107233 0.81 GLS (0.46) GLSMEN1KMT2AL3MBTL1P2RX7
SCHEMBL7428719 0.80 PKM (0.39) MEN1KMT2AALDH1A1MAPTITGA4
SCHEMBL28850201 0.79 ALDH1A1 (0.53) GLSMEN1KMT2AL3MBTL1P2RX7
SCHEMBL916737 0.79 ALDH1A1 (0.53) GLSMEN1KMT2AL3MBTL1P2RX7
SCHEMBL17144723 0.78 EDNRB (0.43) MEN1KMT2AALDH1A1ARSLC6A4
SCHEMBL7739985 0.78 POLB (0.38) KMT2AALDH1A1MAPTITGA4POLB
SCHEMBL13485801 0.78 GLS (0.53) GLSMEN1KMT2AL3MBTL1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447090-B2 Imidazopyridine compounds ASTELLAS PHARMA INC. (JP) 2016-09-20 — — US disclosed
EP-2716642-B1 IMIDAZOPYRIDINE COMPOUND ASTELLAS PHARMA INC (JP) 2016-07-20 — — EP disclosed
US-20140088080-A1 IMIDAZOPYRIDINE COMPOUNDS ASTELLAS PHARMA INC. (JP) 2014-03-27 — — US disclosed
US-8541475-B2 MAO-B inhibitors useful for treating obesity JENRIN DISCOVERY, INC. (US) 2013-09-24 — — US disclosed
US-8541475-B2 MAO-B inhibitors useful for treating obesity JENRIN DISCOVERY, INC. (US) 2013-09-24 — — US disclosed
EP-2042480-B1 AMINOINDAN DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2013-05-01 — — EP disclosed
CN-101489984-B Aminoindan derivative or salt thereof ASTELLAS PHARMA INC 2013-04-03 — — CN disclosed
US-8013018-B2 Aminoindane derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2011-09-06 — — US disclosed
US-20100168068-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2010-07-01 — — US disclosed
US-20100168068-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2010-07-01 — — US disclosed
US-20070088004-A1 Monoamine oxidase-B inhibitors; , and/or cardiometabolic disorders ( hypertension, dyslipidemias, high blood pressure, and insulin resistance); JENRIN DISCOVERY, INC. 2007-04-19 — — US disclosed
US-20070088004-A1 Monoamine oxidase-B inhibitors; , and/or cardiometabolic disorders ( hypertension, dyslipidemias, high blood pressure, and insulin resistance); JENRIN DISCOVERY, INC. 2007-04-19 — — US disclosed
US-7205300-B2 Aryl fused azapolycyclic compounds PFIZER INC (US) 2007-04-17 — — US disclosed
US-7144882-B2 Aryl fused azapolycyclic compounds PFIZER INC (US) 2006-12-05 — — US disclosed
EP-1259489-B1 ARYL FUSED AZAPOLYCYCLIC COMPOUNDS PFIZER PROD INC (US) 2006-06-07 — — EP disclosed
EP-1619192-A2 Aryl fused azapolycyclic compounds Pfizer Products Inc. (US) 2006-01-25 — — EP disclosed
US-6699909-B1 MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS PRESCIENT NEUROPHARMA INC. (CA) 2004-03-02 — — US disclosed
US-6605610-B1 Reducing nicotine addiction; treating neurological and psychological disorders PFIZER INC 2003-08-12 — — US disclosed
US-20030130260-A1 Aryl fused azapolycyclic compounds COE JOTHAM WADSWORTH (US) 2003-07-10 — — US disclosed
WO-1996036596-A1 3,4-DISUBSTITUTED-PHENYLSULPHONAMIDES AND THEIR THERAPEUTIC USE CHIROSCIENCE LIMITED (GB) 1996-11-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088004-A1 Monoamine oxidase-B inhibitors; , and/or cardiometabolic disorders ( hypertension, dyslipidemias, high blood pressure, and insulin resistance); MAOB, MAOA, APOB GLS 730/4885MEN1 2233/4885KMT2A 862/4885
US-20030130260-A1 Aryl fused azapolycyclic compounds GRIN2C, GRIN2A, GRIN3A GLS 2130/4885MEN1 1550/4885KMT2A 363/4885
US-20100168068-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY MAOB, MAOA, GPR119 GLS 661/4885MEN1 3464/4885KMT2A 489/4885
US-20140088080-A1 IMIDAZOPYRIDINE COMPOUNDS GUCY1A1, PDE2A, GUCY1A2 GLS 868/4885MEN1 3450/4885KMT2A 2785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.